.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Chinese Patent Office
Cipla
UBS
McKesson
Daiichi Sankyo
Cantor Fitzgerald
US Army
Covington
US Department of Justice

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,198,882

« Back to Dashboard

Which drugs does patent 9,198,882 protect, and when does it expire?


Patent 9,198,882 protects PROCYSBI and is included in one NDA.

This patent has fifteen patent family members in fifteen countries.

Summary for Patent: 9,198,882

Title:Enterically coated cysteamine, cystamine and derivatives thereof
Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
Inventor(s): Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:14/752,383
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-001Apr 30, 2013RXYesNo9,198,882► Subscribe MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-002Apr 30, 2013RXYesYes9,198,882► Subscribe MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,198,882

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,511,039Enterically coated cysteamine, cystamine and derivatives thereof► Subscribe
8,026,284Enterically coated cystamine, cysteamine and derivatives thereof► Subscribe
9,192,590Enterically coated cysteamine, cystamine and derivatives thereof► Subscribe
8,129,433Enterically coated cysteamine, cystamine and derivatives thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,198,882

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2007210005► Subscribe
BrazilPI0707277► Subscribe
Canada2640531► Subscribe
Cyprus1113690► Subscribe
Denmark1919458► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cerilliant
UBS
Argus Health
Mallinckrodt
Federal Trade Commission
McKesson
Express Scripts
Accenture
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot